Astria Therapeutics, Inc. (ATXS)

NGM – Цена в реальном времени. Валюта: USD

12.58

+12.58 (0.00%)

При закрытии: Jan 22, 2026, 4:00 PM EDT

21.01.2026

Astria Stockholders Vote to Approve Acquisition by BioCryst

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq: ATXS) today announced that at the special meeting of Astria's stockholders held on January 21, 2026, Astria's stockholders voted to approve the acquisition of Astria by BioCryst Pharmaceuticals, Inc. (the “Merger”). The parties expect the Merger to close on or about January 23, 2026, subject to the satisfaction of customary closing conditions. About Astria Therapeutics Astria Therapeutics is a biopharmaceutical company, whose mission i.

30.11.2025

Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold

I maintain a hold rating on Astria Therapeutics with an updated $13 target price following Biocryst's announced acquisition, expecting a 90%+ chance of deal closure by Q1 2026. The investment thesis shifts from clinical catalyst to merger arbitrage, with strong strategic rationale for BCRX to acquire ATXS and minimal regulatory or financial barriers anticipated. Navenibart (STAR-0215) is viewed as a best-in-class prophylaxis agent, and the acquisition offers shareholders a liquidity event, mitigating phase 3 and competitive risks.

12.11.2025

Astria Therapeutics, Inc. (ATXS) Reports Q3 Loss, Misses Revenue Estimates

Astria Therapeutics, Inc. (ATXS) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.42 per share a year ago.

12.11.2025

Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update. “We believe that the proposed transaction with BioCryst provides the best opportunity to advance navenibart, enabling people with HAE to potentially live free from the limitations of their disease,” said Ji.

06.11.2025

Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive results from the full enrollment group of 29 patients in the ALPHA-STAR Phase 1b/2 clinical trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients. Conducted across 20 sites in six countries, the trial demonstrated.

31.10.2025

Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present final results from the ALPHA-STAR Phase 1b/2 trial of navenibart in people living with hereditary angioedema (HAE) at the American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting, taking place November 6-10, 2025 in Orlando, Florida. Aleena Banerji, M.D.

17.10.2025

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Astria Therapeutics, Inc. (NasdaqGM: ATXS) to BioCryst Pharmaceuticals, Inc. (NasdaqGS: BCRX). Under the terms of the proposed transaction, shareholders of Astria will receive $8.55 in cash and 0.59 shares of BioCryst common stock for each share of Astria that they own. KSF is seeking to determ.

Видео

No Data

There is no data to display

Пресс-релизы

21.01.2026

Astria Stockholders Vote to Approve Acquisition by BioCryst

12.11.2025

Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

06.11.2025

Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive results from the full enrollment group of 29 patients in the ALPHA-STAR Phase 1b/2 clinical trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients. Conducted across 20 sites in six countries, the trial demonstrated.

17.10.2025

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

Astria Therapeutics, Inc. (ATXS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Astria Therapeutics, Inc. (ATXS)

Astria Stockholders Vote to Approve Acquisition by BioCryst

Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold

Astria Therapeutics, Inc. (ATXS) Reports Q3 Loss, Misses Revenue Estimates

Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart

Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

Видео

No Data

Пресс-релизы

Astria Stockholders Vote to Approve Acquisition by BioCryst

Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

Astria Stockholders Vote to Approve Acquisition by BioCryst

Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold

Astria Therapeutics, Inc. (ATXS) Reports Q3 Loss, Misses Revenue Estimates

Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart

Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

Видео

No Data

Пресс-релизы

Astria Stockholders Vote to Approve Acquisition by BioCryst

Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

Search stocks

Astria Therapeutics, Inc. (ATXS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Astria Therapeutics, Inc. (ATXS)

Astria Stockholders Vote to Approve Acquisition by BioCryst

Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold

Astria Therapeutics, Inc. (ATXS) Reports Q3 Loss, Misses Revenue Estimates

Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart

Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

Видео

No Data

Пресс-релизы

Astria Stockholders Vote to Approve Acquisition by BioCryst

Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

Astria Stockholders Vote to Approve Acquisition by BioCryst

Astria Therapeutics: Updating Target Price, Biocryst Deal Expected To Go Through, Hold

Astria Therapeutics, Inc. (ATXS) Reports Q3 Loss, Misses Revenue Estimates

Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart

Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

Видео

No Data

Пресс-релизы

Astria Stockholders Vote to Approve Acquisition by BioCryst

Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS